X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://endpts.com/bausch-lomb-and-novaliq-win-approval-for-dry-eye-disease-treatment/
https://www.prnewswire.com/news-releases/bausch--lomb-and-novaliq-announce-us-fda-filing-acceptance-for-investigational-treatment-nov03-perfluorohexyloctane-301617943.html
https://www.prnewswire.com/news-releases/bausch--lomb-and-novaliq-announce-submission-of-new-drug-application-for-investigational-treatment-nov03-perfluorohexyloctane-301581930.html
https://www.bauschhealth.com/news-room/news-releases/news-details/202205030659pr_news_uspr_____ny43632
https://www.prnewswire.com/news-releases/bausch--lomb-presents-data-from-first-pivotal-phase-3-trial-of-investigational-treatment-nov03-perfluorohexyloctane-at-the-american-society-of-cataract-and-refractive-surgery-annual-meeting-301531516.html
https://www.prnewswire.com/news-releases/phase-3-trial-of-shr8058-eye-drops-perfluorohexyloctane-conducted-by-jiangsu-hengrui-pharmaceuticals-in-the-peoples-republic-of-china-shows-statistically-significant-topline-results-301445932.html
https://www.prnewswire.com/news-releases/bausch--lomb-completes-enrollment-of-second-phase-3-study-for-nov03-perfluorohexyloctane-301326484.html
https://www.prnewswire.com/news-releases/bausch--lomb-completes-enrollment-of-first-phase-3-study-for-nov03-perfluorohexyloctane-301210541.html
https://www.prnewswire.com/news-releases/bausch--lomb-completes-enrollment-of-first-phase-3-study-for-nov03-perfluorohexyloctane-301210541.html
https://www.businesswire.com/news/home/20181010005615/en/Novaliq-Raises-New-Capital-Accelerate-Commercialization-Lead
http://www.businesswire.com/news/home/20171206005093/en/Novaliq%E2%80%99s-NovaTears%C2%AEOmega-3-Approved-Europe-Enhanced-Treatment-Evaporative/?feedref=JjAwJuNHiystnCoBq_hl-WFAllVCLJFCqzlmaJ8DKHU4plfPZtlGYRDUHCSmgbii6XkLWuQZD-HgGRnjQvCyg3iCfEFIaJW7-otp9V1XQiK2eHTJy3ZqOEt7kKgLu20J
Market Place
Share 
